Fibrogen Stock Analysis

FGEN -  USA Stock  

USD 12.84  0.47  3.53%

The big decline in price over the last few months for Fibrogen Inc CS could raise concerns from institutional investors as the firm it trading at a share price of 12.84 on very low momentum in volume. The company management teams failed to add value to investors and positioning the firm supply of money to exploit market volatility in June. However, diversifying your holdings with Fibrogen Inc CS or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.12. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Fibrogen Inc partners.
Please check Investing Opportunities.

Search Stock Analysis 

 
Refresh
The Fibrogen Inc stock analysis report makes it easy to digest most publicly released information about Fibrogen Inc and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Fibrogen Stock analysis module also helps to analyze the Fibrogen Inc price relationship with some important fundamental indicators such as market cap and management efficiency.

Fibrogen Stock Analysis Notes

About 79.0% of the company shares are owned by institutional investors. The book value of Fibrogen Inc was currently reported as 4.03. The company recorded a loss per share of 2.01. Fibrogen Inc CS had not issued any dividends in recent years. The entity had 1:1 split on the September 8, 2009. FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Fibrogen Inc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 599 people. To learn more about Fibrogen Inc CS call Thomas Neff at 415 978-1200 or check out www.fibrogen.com.

Fibrogen Inc Quarterly Cost of Revenue

3.4 MillionShare

Fibrogen Inc CS Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Fibrogen Inc's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Fibrogen Inc CS or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Fibrogen Inc CS generates negative expected return over the last 90 days
Fibrogen Inc CS has high historical volatility and very poor performance
The company reported the previous year's revenue of 190.35 M. Net Loss for the year was (182.7 M) with loss before overhead, payroll, taxes, and interest of (85.47 M).
Over 79.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Fibrogen Inc exotic insider transaction detected

Fibrogen Inc CS Upcoming and Recent Events

Earnings reports are used by Fibrogen Inc to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Fibrogen Inc previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report5th of August 2021
Next Earnings Report4th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End7th of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Fibrogen Largest EPS Surprises

Earnings surprises can significantly impact Fibrogen Inc's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2017-03-01
2016-12-31-0.4842-0.54-0.055811 
2016-05-09
2016-03-31-0.5091-0.450.059111 
2018-11-08
2018-09-30-0.4367-0.5-0.063314 
View All Earnings Estimates

Fibrogen Inc SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Fibrogen Inc prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Fibrogen Inc investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Fibrogen Inc CS specific information freely available to individual and institutional investors to make a timely investment decision.
20th of July 2021
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
25th of June 2021
Financial Statements and Exhibits. Other Events
View
17th of June 2021
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
7th of June 2021
Entry into a Material Definitive Agreement
View
27th of May 2021
Submission of Matters to a Vote of Security Holders
View
14th of May 2021
Regulation FD Disclosure
View
10th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
13th of April 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View

Fibrogen Inc Thematic Classifications

In addition to having Fibrogen Inc stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Cancer Fighters IdeaCancer Fighters
Public companies from health care and pharmaceutical sectors that are focused on fighting cancer
Pharmaceutical Products IdeaPharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Fibrogen Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.23 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Fibrogen Inc's market, we take the total number of its shares issued and multiply it by Fibrogen Inc's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Fibrogen Profitablity

Fibrogen Inc's profitability indicators refer to fundamental financial ratios that showcase Fibrogen Inc's ability to generate income relative to its revenue or operating costs. If, let's say, Fibrogen Inc is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Fibrogen Inc's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Fibrogen Inc's profitability requires more research than a typical breakdown of Fibrogen Inc's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (95.98) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (95.21) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.95.
Last ReportedProjected for 2021
Return on Investment(37.36) (40.31) 
Return on Average Assets(0.23) (0.24) 
Return on Average Equity(0.44) (0.47) 
Return on Invested Capital(0.59) (0.61) 
Return on Sales(1.06) (1.09) 

Management Efficiency

The entity has return on total asset (ROA) of (14.06) % which means that it has lost $14.06 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (42.1) %, meaning that it created substantial loss on money invested by shareholders. Fibrogen Inc management efficiency ratios could be used to measure how well fibrogen inc cs manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Investment is estimated to slide to -40.31. The value of Return on Average Assets is estimated to slide to -0.24. Fibrogen Inc Assets Non Current are quite stable at the moment as compared to the past year. The company's current value of Assets Non Current is estimated at 73.62 Million. Revenue to Assets is expected to rise to 0.28 this year, although the value of Total Assets will most likely fall to about 785.7 M.
Last ReportedProjected for 2021
Book Value per Share 4.70  4.33 
Enterprise Value over EBIT(15.00) (16.18) 
Enterprise Value over EBITDA(17.54) (18.93) 
Price to Book Value 8.00  7.60 
Tangible Assets Book Value per Share 9.20  10.72 
Enterprise Value2.9 BB
Tangible Asset Value826.8 M785.7 M

Technical Drivers

As of the 30th of July, Fibrogen Inc shows the mean deviation of 2.98. Fibrogen Inc CS technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Fibrogen Inc CS, which can be compared to its rivals. Please confirm Fibrogen Inc CS jensen alpha, and the relationship between the coefficient of variation and potential upside to decide if Fibrogen Inc CS is priced favorably, providing market reflects its regular price of 12.84 per share. Given that Fibrogen Inc has jensen alpha of (0.59), we urge you to verify Fibrogen Inc CS's prevailing market performance to make sure the company can sustain itself at a future point.

Fibrogen Inc CS Price Movement Analysis

The output start index for this execution was six with a total number of output elements of fifty-five. The Mid-point over period is an average of Fibrogen Inc CS highest and lowest values attained during the given period. View also all equity analysis or get more info about midpoint over period overlap studies indicator.

Fibrogen Inc CS Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fibrogen Inc insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fibrogen Inc's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Fibrogen Inc insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Conterno Enrique A over two weeks ago via Macroaxis 
Fibrogen Inc exotic insider transaction detected
Wettig Thane over a month ago via Macroaxis 
Payment of 2593 shares by Wettig Thane of Fibrogen Inc subject to Rule 16b-3
Pat Cotroneo over a month ago via Macroaxis 
Sale by Pat Cotroneo of 4053 shares of Fibrogen Inc
Chung Christine over a month ago via Macroaxis 
Payment of 2030 shares by Chung Christine of Fibrogen Inc subject to Rule 16b-3
Cravatt Benjamin over two months ago via Macroaxis 
Acquisition by Cravatt Benjamin of 7800 shares of Fibrogen Inc subject to Rule 16b-3
Thomas Kearns over three months ago via Macroaxis 
Exercise or conversion by Thomas Kearns of 6000 shares of Fibrogen Inc subject to Rule 16b-3
Chung Christine over three months ago via Macroaxis 
Payment of 5679 shares by Chung Christine of Fibrogen Inc subject to Rule 16b-3
Wettig Thane over three months ago via Macroaxis 
Acquisition by Wettig Thane of 32100 shares of Fibrogen Inc subject to Rule 16b-3
Kalevi Kurkijarvi over three months ago via Macroaxis 
Exercise or conversion by Kalevi Kurkijarvi of 6000 shares of Fibrogen Inc subject to Rule 16b-3
Kalevi Kurkijarvi over six months ago via Macroaxis 
Exercise or conversion by Kalevi Kurkijarvi of 6000 shares of FibroGen subject to Rule 16b-3
Kalevi Kurkijarvi over six months ago via Macroaxis 
Exercise or conversion by Kalevi Kurkijarvi of 5999 shares of FibroGen subject to Rule 16b-3
Conterno Enrique A over six months ago via Macroaxis 
FibroGen exotic insider transaction detected

Fibrogen Inc Technical and Predictive Indicators

Fibrogen Inc Forecast Models

Fibrogen Inc time-series forecasting models is one of many Fibrogen Inc's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Fibrogen Inc's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Fibrogen Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Fibrogen Inc stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Fibrogen shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Fibrogen Inc. By using and applying Fibrogen Stock analysis, traders can create a robust methodology for identifying Fibrogen entry and exit points for their positions.
Last ReportedProjected for 2021
Operating Margin(40.03) (43.19) 
EBITDA Margin(0.93) (0.96) 
Gross Margin 0.95  0.92 
Profit Margin(1.07) (1.10) 
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Fibrogen Inc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 599 people.

Current Fibrogen Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Fibrogen analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Fibrogen analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
26.67Hold6Odds
Fibrogen Inc CS current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Fibrogen analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Fibrogen stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Fibrogen Inc CS, talking to its executives and customers, or listening to Fibrogen conference calls.
Fibrogen Analyst Advice Details

Fibrogen Stock Analysis Indicators

Fibrogen Inc CS stock analysis indicators help investors evaluate how Fibrogen Inc stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Fibrogen Inc shares will generate the highest return on investment. By understating and applying Fibrogen Inc stock analysis, traders can identify Fibrogen Inc position entry and exit signals to maximize returns.
Quick Ratio3.53
Fifty Two Week Low12.94
Revenue Growth57.50%
Shares Short Prior Month8.46M
Average Daily Volume Last 10 Day2.05M
Average Daily Volume In Three Month1.26M
Shares Percent Shares Out9.54%
Gross Margins-49.20%
Short Percent Of Float10.84%
Forward Price Earnings-6.90
Float Shares85.51M
Fifty Two Week High57.21
Enterprise Value To Ebitda-13.73
Fifty Day Average23.66
Two Hundred Day Average31.01
Enterprise Value To Revenue11.49
Please check Investing Opportunities. Note that the Fibrogen Inc CS information on this page should be used as a complementary analysis to other Fibrogen Inc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Fibrogen Stock analysis

When running Fibrogen Inc CS price analysis, check to measure Fibrogen Inc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fibrogen Inc is operating at the current time. Most of Fibrogen Inc's value examination focuses on studying past and present price action to predict the probability of Fibrogen Inc's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Fibrogen Inc's price. Additionally, you may evaluate how the addition of Fibrogen Inc to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
The market value of Fibrogen Inc CS is measured differently than its book value, which is the value of Fibrogen that is recorded on the company's balance sheet. Investors also form their own opinion of Fibrogen Inc's value that differs from its market value or its book value, called intrinsic value, which is Fibrogen Inc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fibrogen Inc's market value can be influenced by many factors that don't directly affect Fibrogen Inc CS underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fibrogen Inc's value and its price as these two are different measures arrived at by different means. Investors typically determine Fibrogen Inc value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fibrogen Inc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.